Tag: Maralixibat

CANbridge doses first patient in phase 2 EMBARK study of CAN108 in BA

pallavi123- July 17, 2022

CANbridge Pharmaceuticals has dosed the first patient in the phase 2 EMBARK study of CAN108 (maralixibat) in biliary atresia (BA) in China. The clinical trial ... Read More

Mirum gets FDA breakthrough therapy status for maralixibat for Alagille syndrome

pharmanewsdaily- October 29, 2019

Mirum Pharmaceuticals has secured the breakthrough therapy designation for maralixibat from the US Food and Drug Administration (FDA) for the treatment of pruritus associated with ... Read More

Mirum Pharmaceuticals raises $120m to advance Maralixibat into phase 3

pharmanewsdaily- December 2, 2018

Mirum Pharmaceuticals, a clinical stage pharma company in San Diego, has raised $120 million in a Series A funding round to support the development of ... Read More